Q: Make exam oriented concise notes on the following thing from the given source A: Here are concise, exam-oriented notes on Menopause based on the provided source Textbook of Gynecology, Chapter 6: --- MENOPAUSE - EXAM NOTES --- DEFINITION - Permanent cessation of menstruation at end of reproductive life due to loss of ovarian follicular activity - Diagnosed retrospectively - after 12 consecutive months of amenorrhea without any pathology - Menopause transition perimenopause: 4-7 years on either side of menopause - Postmenopause: Phase after menopause - Average age: 50 years range 45-55 years - Age is genetically predetermined - NOT related to pregnancies, lactation, OCP use, race, height, or weight --- ENDOCRINOLOGY HPG Axis Changes Hormone Change Reason --------- FSH Markedly elevated 40 mIU/mL Loss of negative feedback ↓estradiol + ↓inhibin LH Elevated 3-fold less than FSH Same as above Estradiol Falls to 10-20 pg/mL from 50-300 pg/mL Follicular depletion Inhibin Decreased Granulosa cell loss Post-menopausal Estrogens - Predominant estrogen = Estrone not estradiol - Estrone level: 30-70 pg/mL Estradiol: 10-20 pg/mL - Source: Peripheral aromatization of androgens mainly in muscle & adipose tissue - Estrone is biologically 1/10th as potent as estradiol - Obese women → more estrone → less osteoporosis but MORE risk of endometrial carcinoma Androgens - Ovarian stromal cells continue producing androgens androstenedione, testosterone - Net effect: ↑ facial hair, voice change Progesterone - Only trace amounts adrenal origin - AMH markedly decreased marker of ovarian reserve --- ORGAN CHANGES Organ Change ------ Ovaries Shrink, wrinkled, no secretory activity Fallopian tubes Atrophy, cilia disappear Uterus Smaller; body:cervix ratio reverts to 1:1 Vagina Narrow, less elastic, no glycogen, alkaline pH, maturation index 10/85/5 Vulva Atrophy, narrow introitus Breast Fat reabsorbed, pendulous Bladder/Urethra Atrophic → dysuria, frequency, stress incontinence --- MENOPAUSAL SYMPTOMS mnemonics: VU-OSCP-CS-D A. Vasomotor most characteristic - Hot flashes - sudden heat + profuse sweating - Night sweats, palpitations, fatigue - Mechanism: GnRH pulse + ↓estrogen → reset of thermoregulatory center hypothalamus; coincides with LH surge - Lasts 1-10 minutes B. Urogenital Atrophy - Dyspareunia, vaginal dryness, pruritus, leucorrhoea - Urinary: urgency, dysuria, recurrent UTI, stress incontinence C. Psychological - Anxiety, irritability, insomnia, mood swings, poor memory, depression - Estrogen ↑ opioid neurotransmitter activity → important for memory D. Skin & Hair - Thinning, wrinkling "purse string" around mouth, "crow's feet" - Collagen content decreases 1-2%/year - Some pubic/axillary hair loss E. Sexual Dysfunction - ↓ libido due to estrogen deficiency + psychological factors --- BONE METABOLISM - Post-menopause: bone loss 3-5% per year due to ↓estrogen - BMD reported as T-Scores - Normal: T-score between +2.5 and -1.0 - Osteopenia: T-score -1.0 to -2.5 - Osteoporosis: T-score -2.5 → ↑ fracture risk - Osteoporosis may be Primary Type 1 = estrogen loss / Secondary Type 2 = endocrine abnormality - Fractures: vertebral body, femoral neck, distal forearm Colles' - Detection: DEXA scan preferred; CT scan more radiation - FRAX tool WHO 2004: calculates 10-year fracture risk Risk Factors for Osteoporosis Age 65, white/Asian race, low BMI, ↓estrogen, family history, smoking, ↓calcium/Vit D, ↑caffeine/alcohol, corticosteroids, GnRH analogs, rheumatoid arthritis, hyperparathyroidism, thyroid disorders --- CARDIOVASCULAR EFFECTS - Estrogen protects against CVD: - ↑ HDL2, ↓ LDL, ↓ total cholesterol - Inhibits platelet & macrophage aggregation - Stimulates NO + prostacyclin release → vasodilation - Antioxidant property prevents LDL oxidation - Post-menopause: ↑ risk of IHD, coronary artery disease, stroke - Risk factors for CVD: hypertension, familial hyperlipidemia, smoking, impaired glucose tolerance --- DIAGNOSIS OF MENOPAUSE 1. Cessation of menstruation for 12 consecutive months 2. Average age: 50 years 3. Hot flashes + night sweats classic symptoms 4. Vaginal cytology: maturation index 10/85/5 5. Serum estradiol: 20 pg/mL 6. FSH 40 mIU/mL three values at weekly intervals --- MANAGEMENT Non-Hormonal Treatment Intervention Detail ------ Lifestyle modification Weight-bearing exercise, ↓caffeine/smoking/alcohol Calcium supplementation 1-1.5 g/day Vitamin D 1500-2000 IU/day Bisphosphonates ↓ osteoclastic resorption; preferred in older women; taken on empty stomach, remain upright 30 min; SE: GI ulceration, osteomyelitis, osteonecrosis of jaw Calcitonin Inhibits bone resorption; give with calcium + Vit D SERMs Raloxifene ↑ BMD, ↓ LDL, ↑ HDL2; ↓ breast & endometrial cancer risk; does NOT improve hot flashes or urogenital atrophy Clonidine α₂ agonist ↓ hot flash severity/duration; SE: hypotension, dry mouth Paroxetine/Venlafaxine ↓ hot flash frequency/severity Gabapentin Controls hot flashes Phytoestrogens/Soy ↓ vasomotor symptoms, osteoporosis, CVD Vitamin E ↓ hot flashes by 25% --- HORMONE THERAPY HT Indications - Relief of menopausal symptoms vasomotor, urogenital - Prevention of osteoporosis - Quality of life - Special: premature ovarian failure, gonadal dysgenesis, surgical/radiation menopause Benefits of HT - Vasomotor improvement: 70-80% - Urogenital atrophy improvement - ↑ BMD by 2-5% - ↓ vertebral & hip fractures: 25-50% - ↓ colorectal cancer: 20% - Possible cardioprotection Risks of HT Risk Detail ------ Endometrial cancer Unopposed estrogen → hyperplasia/carcinoma; add progestin if intact uterus Breast cancer Combined E+P long-term → ↑ risk RR 1.26 VTE ↑ with combined oral E+P; transdermal does NOT have same risk CHD Combined HT: RR 1.29; hypertension NOT a risk of HT Gallbladder disease Increased incidence Dementia/Alzheimer NOT benefited Contraindications to HT - Known/suspected breast cancer - Undiagnosed genital tract bleeding - Estrogen-dependent neoplasm - History of VTE / active DVT - Active liver disease - Prior cholestatic jaundice caution - Gallbladder disease - Prior endometriosis caution HT Preparations - Without uterus hysterectomy: Estrogen alone oral CEE 0.3-0.625 mg/day - With intact uterus: Estrogen + cyclic progestin estrogen 25 days + progestin last 12-14 days OR continuous combined - Progestins used: MPA 2.5-5 mg/day, micronized progesterone 100-300 mg/day, dydrogesterone 5-10 mg/day - Transdermal: Avoids first-pass metabolism; ↓ VTE/gallbladder risk - Vaginal cream: CEE 1.25 mg/day - best for atrophic vaginitis - Levonorgestrel IUS LNG-IUS: Used to minimize systemic progestin SE - Key principle: Use lowest effective dose for shortest period of time ACOG 2008 Monitoring During HT Table 6.4 - Physical exam + pelvic exam - Blood pressure - Breast exam + mammography - Cervical cytology - Pelvic USG endometrial thickness 5 mm - Serum estradiol should be 100 pg/mL during HT --- OTHER AGENTS - Tibolone steroid, 19-nortestosterone derivative: Estrogenic + progestogenic + androgenic; prevents osteoporosis, atrophic changes, hot flashes; ↑ libido; endometrium atrophic - dose 2.5 mg/day - Testosterone: For hypoactive sexual desire disorder HSDD - PTH Teriparatide: SC injection; ↑ osteoblast activity; NOT used 2 years; SE: leg cramps, nausea, headache - CAM Acupuncture: ↓ hot flash frequency and intensity --- ABNORMAL MENOPAUSE - Premature menopause: Menopause at or before age 40 familial diathesis common - Delayed menopause: Fails to occur even beyond 55 years - Artificial menopause: Surgical bilateral oophorectomy or radiation/chemotherapy-induced cessation - Surgical menopause = more troublesome than natural - Radiation menopause: Not permanent; may resume after 2 years --- HIGH-YIELD EXAM POINTS 1. Menopause diagnosed retrospectively after 12 months amenorrhea 2. FSH is first to rise; LH rises later 3-fold less 3. Predominant estrogen post-menopause = Estrone peripheral aromatization 4. Hot flash coincides with GnRH pulse + LH surge 5. Vaginal maturation index post-menopause = 10/85/5 parabasal predominance 6. Obese women: ↑ estrone → ↓ osteoporosis but ↑ endometrial cancer 7. DEXA is gold standard for BMD measurement 8. Add progestin to HT if uterus is intact prevents endometrial cancer 9. Transdermal estrogen: ↓ VTE risk compared to oral 10. Raloxifene = SERM; does NOT help hot flashes; ↓ breast cancer 11. Bisphosphonates: Take on empty stomach, remain upright 30 min 12. Teriparatide: Only agent that stimulates new bone formation; max 2 years Q: Make a short note on this only A: --- MENOPAUSE & MENOPAUSAL SYMPTOMS - Short Note --- MENOPAUSE - Definition: Permanent cessation of menstruation due to loss of ovarian follicular activity; diagnosed retrospectively after 12 consecutive months of amenorrhea - Average age: 50 years range 45-55 - Age is genetically predetermined - NOT related to pregnancies, OCP use, lactation, race, or weight - Menopause transition perimenopause: 4-7 years on either side of menopause; characterized by elevated FSH, variable cycle length, irregular/missed periods - Postmenopause: Phase after last period Key Hormonal Changes Hormone Level Reason --------- FSH Markedly ↑ 40 mIU/mL ↓ Estradiol + ↓ Inhibin lost negative feedback Estradiol Falls to 10-20 pg/mL Follicular depletion Predominant estrogen Estrone peripheral aromatization Aromatization in muscle/adipose - Menstruation ceases when estradiol falls to 20 pg/mL → no endometrial growth --- MENOPAUSAL SYMPTOMS 1. Vasomotor Most Characteristic - Hot flash: Sudden feeling of heat + profuse sweating - Also: night sweats, palpitations, fatigue, weakness - Mechanism: ↓ Estrogen → reset of thermoregulatory center in hypothalamus associated with GnRH center; coincides with LH surge - Duration: 1-10 minutes; may be unbearable at night 2. Urogenital Atrophy - Vaginal: Dyspareunia, dryness, pruritus, leucorrhoea; vaginal pH becomes alkaline; maturation index = 10/85/5 - Urinary: Urgency, dysuria, frequency, recurrent UTI, stress incontinence - Cause: Estrogen receptors present in urethra, bladder, vaginal wall - deficiency causes atrophic epithelial changes 3. Psychological - Anxiety, irritability, insomnia, mood swings, poor memory, depression - Estrogen ↑ opioid neurotransmitter activity → important for memory & cognition 4. Skin & Hair - Thinning, loss of elasticity, wrinkling "purse string" around mouth, "crow's feet" - Collagen decreases 1-2%/year - Loss of pubic/axillary hair ↓ estrogen with normal testosterone levels 5. Sexual Dysfunction - ↓ Libido due to estrogen deficiency + psychological factors depression, anxiety 6. Osteoporosis & Fracture - Bone loss 3-5%/year post-menopause - Fractures: vertebral, femoral neck, Colles' distal forearm 7. Cardiovascular - ↑ risk of IHD, coronary artery disease, stroke due to loss of estrogen's protective effects 8. Dementia - Estrogen improves cerebral perfusion & cognition; however, HT's effect on preventing Alzheimer's is unclear --- DIAGNOSIS 1. 12 months amenorrhea during climacteric 2. Classic symptoms: hot flash + night sweats 3. FSH 40 mIU/mL x3 at weekly intervals 4. Serum estradiol 20 pg/mL 5. Vaginal cytology: maturation index 10/85/5 --- HIGH-YIELD EXAM POINTS - Hot flash = most characteristic symptom - Hot flash mechanism: GnRH center in hypothalamus + LH surge - Vaginal pH becomes alkaline post-menopause loss of lactobacilli/glycogen - Estrone is predominant post-menopausal estrogen from peripheral aromatization - Obese women: more estrone → ↓ hot flashes but ↑ endometrial carcinoma risk - Menopause diagnosed retrospectively - never prospectively Q: Make an exam oriented good notes on chp disease of alimentary tract from the given source A: Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
